Rafael Holdings, Inc., is a U.S.-based company focused on advancing innovative treatments in oncology. It oversees a portfolio of companies developing novel therapeutics targeting cancer metabolism and related technologies. The firm's lead therapeutic candidate, CPI-613, aims to disrupt cancer cell energy production and is undergoing various clinical trials, including Phase 3 studies. Rafael Holdings also owns equity in Lipomedix Pharmaceuticals, which is working on drug delivery systems to enhance cancer therapies